|
Patent landscape, scope, and claims: |
United States Patent 6,048,859 (emesis prevention) claims, scope, and US patent landscape: what is protected, what’s likely generic-design-around safe, and where infringement exposure sits
US Patent 6,048,859 claims combination methods for prevention or treatment of emesis (vomiting) in a mammal using a 5HT3 receptor antagonist administered in conjunction with a morpholine-class compound defined by a broad, substitution-variable structural Markush framework and, in narrower dependent claims, by specific named stereoisomers/chemical variants.
This is a method-of-use + defined chemical compound in combination patent. It is not a composition-of-matter claim on the 5HT3 antagonist itself. Practical infringement turns on whether a generic or branded competitor administers the 5HT3 antagonist and an infringing morpholine compound together for emesis.
What is US Patent 6,048,859, and what does it claim?
Core independent claim structure (Claim 1)
- A method for “prevention or treatment of emesis” in a mammal
- Comprises administering an “effective amount” of:
- a 5HT3 receptor antagonist, and
- a compound represented by a structural formula (a morpholine scaffold with benzyl-oxy (benzyloxy) type substitutions and heterocycle-containing side groups)
- plus pharmaceutically acceptable salts
Key legal/technical consequence: the claim is triggered by use/administration, not manufacture or formulation alone.
What is the chemical scope of the “compound” in Claim 1?
Claim 1 defines a Markush-style structural formula with a highly permissive substitution set across multiple variables:
- R1: extremely broad selection set including H, C1-6 alkyl substituted with numerous functional groups, multiple heterocycles (benzimidazolyl, pyridyl, tetrazolyl, etc.), CN, halo (F/Cl/Br/I), nitro, CF3, thioethers, sulfoxide/sulfone-like motifs (via SR/SO/R14 constructs), amide/ester-like moieties (NR9 COR10, NR9 CO2 R10, CONR9 R10, COR9, CO2 R9), and linker-like groups
- R2, R3: similarly broad subsets (H, C1-6 alkyl, alkenyl, alkynyl, phenyl) with substituents like halo, CN, CF3, amide/ester-like groups, and heterocycle selections in R3
- R6, R7, R8: broad (H, C1-6 alkyl, alkenyl, alkynyl, phenyl) with halo/CN/CF3 and hetero/bioisosteric-like replacements
- X: bridging atom selection: O, S, SO, SO2
- Y: bond/hetero-atom selection: single bond, O, S, CO, CH2, CHR15, or CR15R16
- Z: H or C1-6 alkyl (dependent claims tighten it to shorter alkyl and methyl)
- R11, R12, R13: mirror selection sets of R6/R7/R8
Practical scope read:
- The morpholine scaffold is the anchor.
- The aromatic “benzyl-oxy” type substitution pattern and the functionalized side chain/heterocycle group are variable but constrained to a finite set of substitution classes.
- Even though the independent claim reads as “wide,” it is still chemically bounded to the specific scaffold and linkage classes recited.
How do Claims 2–5 narrow the compound within Claim 1?
These dependent claims introduce narrower, enumerated selections:
- Claim 2: narrows to cases where R1 is C1-6 alkyl substituted with particular heterocycles (benzimidazolyl/imidazolyl/isooxazolyl/isothiazolyl/oxadiazolyl/pyrazinyl/pyrazolyl/pyridyl/pyrrolyl/tetrazolyl/thiadiazolyl/triazolyl/piperidinyl) and limits the substituents on that heterocycle
- Claims 3–4: provide simplified selection sets for R2/R3 and for halogens and CF3 at R6/R7/R8, and tightens X and Y to:
- Claim 5: fixes Z = CH3
Infringement implication: If an accused product uses a morpholine derivative outside these narrower contingencies, it may still fall under Claim 1 if the broader Markush substitutions match. The dependent claims mainly strengthen alternative claim paths.
What are Claims 6–14 doing (named substructures and enumerated formula alternatives)?
- Claims 6–8: specify particular R1 substituent classes and named methylene-heterocycle mappings:
- (1,2,4-triazolo)methyl and (5-oxo-1H,4H-1,2,4-triazolo)methyl
- (1,3-imidazolo)methyl and (2-oxo-1,3-imidazolo)methyl
- Claims 9–14: provide multiple structural formula instantiations “structural formula II/III/…/…,” each still tied to the same variable definitions.
Infringement implication: these “formula-specific” dependents reduce the chance that an accused compound avoids the claim by exploiting drafting ambiguities in the generic Markush description.
Which compounds are explicitly listed in Claim 15 (enumerated chemical list)?
Claim 15 creates a second, more explicit claim path: a method of emesis prevention/treatment with
- a 5HT3 receptor antagonist, plus
- a compound selected from a long enumerated list of specific morpholine stereoisomers and chemical variants.
This list contains many examples that share motifs, notably:
- 3,5-bis(trifluoromethyl)benzyloxy substituted morpholine backbones
- varying benzyl substituents (dimethyl, dichloro, difluoro, tert-butyl, CF3 variants, thiomethyl, methoxy variants, etc.)
- heterocycle substituents in the morpholine side chain such as (1,2,4-triazolo)methyl and (5-oxo-1H,4H-1,2,4-triazolo)methyl
- imidazolo variants including 2-oxo-1,3-imidazolo
- stereochemical descriptors (2R/2S, 3R/3S, 4- and 6- substitutions and “methyl-morpholine” variants)
Key legal effect: enumerated selection narrows “what counts” compared to Claim 1, but it also means that infringement can be proven by identifying a specific matching compound (including stereochemistry) rather than arguing Markush coverage.
What is Claim 16’s scope (single-compound pickoff)?
- Claim 16 targets a particular compound:
- “2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-morpholine”
- administered in conjunction with a 5HT3 receptor antagonist
Dependent claims 17–19 name specific 5HT3 antagonists:
- ondansetron
- granisetron
- tropisetron
Infringement implication: If a product uses this exact morpholine and is dosed with one of the named 5HT3 antagonists (or a non-named 5HT3 antagonist still covered by Claim 1), Claim 16 is a high-confidence hook.
What are Claims 20–23 doing (second explicit morpholine and named 5HT3 antagonists)?
- Claim 20 introduces another explicitly described morpholine compound (structural formula reference) plus 5HT3 antagonist combination.
- Dependent 21–23 again name:
- ondansetron
- granisetron
- tropisetron
Infringement implication: this gives the patent at least two concrete “compound pickoffs” that can be used for claim charting and licensing leverage.
What does this patent likely protect operationally in a pharma product lifecycle?
What conduct infringes
- Medical use where the regimen includes:
- a 5HT3 receptor antagonist, and
- an administration of an infringing morpholine compound
for prevention or treatment of emesis in a mammal.
What conduct likely does not infringe
- A standalone morpholine compound used without a 5HT3 antagonist (unless another independent claim exists, not shown here).
- A 5HT3 antagonist used without the morpholine compound.
- Manufacturing-only activities where the combination is not “administered” for emesis (method-of-use claims typically still can be enforced via induced/infringing “use,” depending on facts and claim language, but clean “manufacture only” designs around are common in practice).
How broad is “5HT3 receptor antagonist” as used in the claims?
The independent claim language just says “a 5HT3 receptor antagonist” without limiting it by structure.
Dependent claims identify common antagonists:
- ondansetron
- granisetron
- tropisetron
Landscape effect: any emesis regimen using one of these standard antagonists in combination with an infringing morpholine is squarely within the targeted “combination use” pattern.
How strong is the patent estate likely to be against generics or biosimilar-type entrants (in method-of-use framing)?
Patent landscape beyond US 6,048,859: how to evaluate relative exclusivity using only what’s structurally knowable from this claim set
Because the independent claim is a method-of-use with defined chemistry, the surrounding landscape in practice typically includes:
- earlier priority chemistry patents covering the morpholine compound class
- later continuation or divisionals covering:
- narrower substructures,
- specific stereoisomers,
- alternative linkages (X and Y variants),
- and combination regimens with specific 5HT3 antagonists
From the claim set alone, the patent is written as if it sits in a family where:
- Claim 1 is the “broad Markush,”
- Claims 6–14 are “fall-back structure-specific dependents,”
- Claim 15 is a “catalog of covered stereoisomers,”
- Claims 16–20 are “litigation-friendly pickoffs,”
- Claims 17–19 and 21–23 are “name the common 5HT3 antagonists” dependents.
Actionable takeaway: for licensing and design-around analysis, the practical risk is not just whether a competitor’s morpholine analogue falls under Claim 1. It is whether it matches any enumerated entry in Claim 15 or any exact pickoff like Claim 16/20.
Key claim-scope mapping: what specific claim elements must be present in an accused regimen?
| Element in the patent |
How it narrows infringement |
Practical evidence to collect |
| “Method for prevention or treatment of emesis” |
Requires the use context/indication to map to emesis prevention/treatment |
label, clinical protocol, prescribing information, trial protocol |
| “a 5HT3 receptor antagonist” |
Any 5HT3 antagonist likely included; dependent claims highlight ondansetron/granisetron/tropisetron |
formulation and administered drug list |
| “in conjunction with” |
Combination regimen; coadministration timing could matter for “in conjunction” arguments |
regimen sheets, dosing records |
| Morpholine compound of defined formula |
Must match Markush scaffold + substituent constraints |
chemical identity (stereochemistry), impurity/composition specs, synthetic route info |
| Enumerated compound list (Claim 15) |
Exact matching for specific listed stereoisomers/variants |
structure assignment and stereochemical confirmation |
| Pickoff compound (Claim 16) |
Exact chemical match |
chemical structure confirmation vs the claim language |
When does the patent lose exclusivity?
No filing date, priority date, term adjustment, or expiration data is provided in the record above, so an exclusivity/expiration timeline cannot be calculated.
Key Takeaways
- US 6,048,859 is a method-of-use patent covering emesis prevention/treatment via combination administration of a 5HT3 receptor antagonist and a morpholine-derived compound defined by broad Markush substitutions plus extensive enumerated stereochemical examples.
- Claim 1 is the breadth engine (wide substitution sets over R1/R2/R3/R6/R7/R8 and linkage options X and Y; Z limited to H/C1-6 alkyl).
- Claim 15 is the litigation leverage engine (explicit catalog of many stereoisomers/chemical variants), reducing uncertainty in infringement analysis.
- Claims 16–20 are pickoff claims targeting specific morpholine structures, and Claims 17–19 and 21–23 anchor common 5HT3 antagonists (ondansetron, granisetron, tropisetron).
- The highest generic/design-around risk arises from any competitor regimen that administers a covered morpholine variant in combination with a 5HT3 antagonist for the emesis indication.
FAQs
- Does US 6,048,859 cover preventing nausea as well as vomiting?
- If a product uses only granisetron and not ondansetron, is it still covered?
- Can a generic avoid infringement by using a different antiemetic class instead of a 5HT3 antagonist?
- How much do stereochemistry details matter under the enumerated compound list in Claim 15?
- If a competitor modifies the benzyl-oxy/ethoxy linkage (X/Y/Z), can it still fall within Claim 1?
References
- United States Patent No. 6,048,859, “Method for the prevention or treatment of emesis,” claims 1-23 (as provided in the prompt).
More… ↓
⤷ Start Trial
|
